High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

By P. Ridker. Circulation, 2001

1,395 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/d8eb7f3f0873a13df856fd279f6127ab934d223a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. P. Ridker
2. N. Rifai
3. G. Assmann
4. S. Laurent
5. Richard J. Johnson
6. E. Danielson
7. M. Albert
8. Peter Libby

In Epidemiology

1. P. Ridker
2. N. Rifai
3. Richard J. Johnson
4. E. Danielson
5. M. Albert
6. Peter Libby
7. L. Melvin
8. G. Hansson

In Surgery

1. P. Ridker
2. N. Rifai
3. G. Assmann
4. E. Danielson
5. M. Albert
6. Peter Libby
7. L. Melvin
8. G. Hansson

Citations in the corpus

• Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. (2005, background): “Discussion Systemic inflammation is an important determinant of cardiovascular morbidity (1,2).”
• Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. (2001, methodology): “Furthermore, the addition of CRP screening to standard lipid evaluation appears to provide an improved method of determining global vascular risk.(13) This latter observation is clinically important because combined CRP and lipid screening may provide an improved method to target statin therapy, par”
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension (2007, background): “(168) Although high sensitivity C reactive protein (hsCRP) has been reported to predict the incidence of cardiovascular events in several clinical settings, (169) its added value in determining total cardiovascular risk is uncertain, (170) except in patients with metabolic syndrome in whom hsCRP val”
• Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. (2004, background): “The CRP levels climbed during the 88-h vigil, through the low prediction zone (0.01 to 0.07 mg/dl), and approached levels associated with mild risk (0.07 to 0.11 mg/dl) for myocardial infarction and stroke ( 19 ) .I n the PSD study, subjects moved from levels consistent with mild risk to levels repr”